Faecal ribosomal protein L19 is a genetic prognostic factor for survival in colorectal cancer

C. J. Huang, C. C. Chien, S. H. Yang, C. C. Chang, H. L. Sun, Y. C. Cheng, C. C. Liu, S. C. Lin, C. M. Lin

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Ribosomal proteins are encoded by a gene family, members of which are overexpressed in human cancers. Many of them have been found, using oligonucleotide microarray hybridization, to be differentially expressed in the faeces of patients with various stages of col-orectal cancer (CRC). The gene encoding ribosomal protein L19 (RPL19), a prognostic marker for human prostate cancer, is differentially expressed in CRC patients. Measurement of faecal RPL19 mRNA might improve prognostic prediction for CRC patients. Using quantitative real-time reverse transcription PCR, levels of RPL19 mRNA were detected in samples of colonic tissues from 44 CRC patients, in the faeces of 54 CRC patients and 15 controls, and in 11 colonic cell lines. Seven of 24 patients with late-stage CRC (Dukes' stages C and D) expressed over 2-fold more RPL19 in colonic tumour tissues than in corresponding normal tissues (P = 0.038). The mean faecal RPL19 mRNA levels of late-staged patients were higher than those of controls (P = 0.003) and early-staged patients (P = 0.008). Patients with both high serum levels of carcinoembryonic antigen (CEA; >5 ng/mL) and high-faecal RPL19 mRNA (≥0.0069) had higher risk (odds ratio, 8.0; P = 0.015) and lower overall 48-month survival (33.8 ± 13.7%, P = 0.013). Oligonucleotide microarray hybridization analysis of faecal molecules identified gene transcripts differentially present in faeces. In conclusion, faecal RPL19 expression is associated with advanced tumour stages and addictive to serum CEA in predicting prognosis of CRC patients.

Original languageEnglish
Pages (from-to)1936-1943
Number of pages8
JournalJournal of Cellular and Molecular Medicine
Volume12
Issue number5B
DOIs
Publication statusPublished - Oct 2008

Fingerprint

Ribosomal Proteins
Colorectal Neoplasms
Survival
Neoplasms
Feces
Messenger RNA
Oligonucleotide Array Sequence Analysis
Odds Ratio
Genes
Carcinoembryonic Antigen
Microarray Analysis
Serum
Reverse Transcription
Prostatic Neoplasms
Cell Line
Polymerase Chain Reaction

Keywords

  • Colorectal cancer
  • Oligonucleotide microarray
  • Overall 48-month survival
  • Prognostic marker
  • Ribosomal protein L19

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Medicine

Cite this

Faecal ribosomal protein L19 is a genetic prognostic factor for survival in colorectal cancer. / Huang, C. J.; Chien, C. C.; Yang, S. H.; Chang, C. C.; Sun, H. L.; Cheng, Y. C.; Liu, C. C.; Lin, S. C.; Lin, C. M.

In: Journal of Cellular and Molecular Medicine, Vol. 12, No. 5B, 10.2008, p. 1936-1943.

Research output: Contribution to journalArticle

Huang, C. J. ; Chien, C. C. ; Yang, S. H. ; Chang, C. C. ; Sun, H. L. ; Cheng, Y. C. ; Liu, C. C. ; Lin, S. C. ; Lin, C. M. / Faecal ribosomal protein L19 is a genetic prognostic factor for survival in colorectal cancer. In: Journal of Cellular and Molecular Medicine. 2008 ; Vol. 12, No. 5B. pp. 1936-1943.
@article{61c57d3a5624452cb2aeb26304a42e7d,
title = "Faecal ribosomal protein L19 is a genetic prognostic factor for survival in colorectal cancer",
abstract = "Ribosomal proteins are encoded by a gene family, members of which are overexpressed in human cancers. Many of them have been found, using oligonucleotide microarray hybridization, to be differentially expressed in the faeces of patients with various stages of col-orectal cancer (CRC). The gene encoding ribosomal protein L19 (RPL19), a prognostic marker for human prostate cancer, is differentially expressed in CRC patients. Measurement of faecal RPL19 mRNA might improve prognostic prediction for CRC patients. Using quantitative real-time reverse transcription PCR, levels of RPL19 mRNA were detected in samples of colonic tissues from 44 CRC patients, in the faeces of 54 CRC patients and 15 controls, and in 11 colonic cell lines. Seven of 24 patients with late-stage CRC (Dukes' stages C and D) expressed over 2-fold more RPL19 in colonic tumour tissues than in corresponding normal tissues (P = 0.038). The mean faecal RPL19 mRNA levels of late-staged patients were higher than those of controls (P = 0.003) and early-staged patients (P = 0.008). Patients with both high serum levels of carcinoembryonic antigen (CEA; >5 ng/mL) and high-faecal RPL19 mRNA (≥0.0069) had higher risk (odds ratio, 8.0; P = 0.015) and lower overall 48-month survival (33.8 ± 13.7{\%}, P = 0.013). Oligonucleotide microarray hybridization analysis of faecal molecules identified gene transcripts differentially present in faeces. In conclusion, faecal RPL19 expression is associated with advanced tumour stages and addictive to serum CEA in predicting prognosis of CRC patients.",
keywords = "Colorectal cancer, Oligonucleotide microarray, Overall 48-month survival, Prognostic marker, Ribosomal protein L19",
author = "Huang, {C. J.} and Chien, {C. C.} and Yang, {S. H.} and Chang, {C. C.} and Sun, {H. L.} and Cheng, {Y. C.} and Liu, {C. C.} and Lin, {S. C.} and Lin, {C. M.}",
year = "2008",
month = "10",
doi = "10.1111/j.1582-4934.2008.00253.x",
language = "English",
volume = "12",
pages = "1936--1943",
journal = "Journal of Cellular and Molecular Medicine",
issn = "1582-1838",
publisher = "Wiley-Blackwell",
number = "5B",

}

TY - JOUR

T1 - Faecal ribosomal protein L19 is a genetic prognostic factor for survival in colorectal cancer

AU - Huang, C. J.

AU - Chien, C. C.

AU - Yang, S. H.

AU - Chang, C. C.

AU - Sun, H. L.

AU - Cheng, Y. C.

AU - Liu, C. C.

AU - Lin, S. C.

AU - Lin, C. M.

PY - 2008/10

Y1 - 2008/10

N2 - Ribosomal proteins are encoded by a gene family, members of which are overexpressed in human cancers. Many of them have been found, using oligonucleotide microarray hybridization, to be differentially expressed in the faeces of patients with various stages of col-orectal cancer (CRC). The gene encoding ribosomal protein L19 (RPL19), a prognostic marker for human prostate cancer, is differentially expressed in CRC patients. Measurement of faecal RPL19 mRNA might improve prognostic prediction for CRC patients. Using quantitative real-time reverse transcription PCR, levels of RPL19 mRNA were detected in samples of colonic tissues from 44 CRC patients, in the faeces of 54 CRC patients and 15 controls, and in 11 colonic cell lines. Seven of 24 patients with late-stage CRC (Dukes' stages C and D) expressed over 2-fold more RPL19 in colonic tumour tissues than in corresponding normal tissues (P = 0.038). The mean faecal RPL19 mRNA levels of late-staged patients were higher than those of controls (P = 0.003) and early-staged patients (P = 0.008). Patients with both high serum levels of carcinoembryonic antigen (CEA; >5 ng/mL) and high-faecal RPL19 mRNA (≥0.0069) had higher risk (odds ratio, 8.0; P = 0.015) and lower overall 48-month survival (33.8 ± 13.7%, P = 0.013). Oligonucleotide microarray hybridization analysis of faecal molecules identified gene transcripts differentially present in faeces. In conclusion, faecal RPL19 expression is associated with advanced tumour stages and addictive to serum CEA in predicting prognosis of CRC patients.

AB - Ribosomal proteins are encoded by a gene family, members of which are overexpressed in human cancers. Many of them have been found, using oligonucleotide microarray hybridization, to be differentially expressed in the faeces of patients with various stages of col-orectal cancer (CRC). The gene encoding ribosomal protein L19 (RPL19), a prognostic marker for human prostate cancer, is differentially expressed in CRC patients. Measurement of faecal RPL19 mRNA might improve prognostic prediction for CRC patients. Using quantitative real-time reverse transcription PCR, levels of RPL19 mRNA were detected in samples of colonic tissues from 44 CRC patients, in the faeces of 54 CRC patients and 15 controls, and in 11 colonic cell lines. Seven of 24 patients with late-stage CRC (Dukes' stages C and D) expressed over 2-fold more RPL19 in colonic tumour tissues than in corresponding normal tissues (P = 0.038). The mean faecal RPL19 mRNA levels of late-staged patients were higher than those of controls (P = 0.003) and early-staged patients (P = 0.008). Patients with both high serum levels of carcinoembryonic antigen (CEA; >5 ng/mL) and high-faecal RPL19 mRNA (≥0.0069) had higher risk (odds ratio, 8.0; P = 0.015) and lower overall 48-month survival (33.8 ± 13.7%, P = 0.013). Oligonucleotide microarray hybridization analysis of faecal molecules identified gene transcripts differentially present in faeces. In conclusion, faecal RPL19 expression is associated with advanced tumour stages and addictive to serum CEA in predicting prognosis of CRC patients.

KW - Colorectal cancer

KW - Oligonucleotide microarray

KW - Overall 48-month survival

KW - Prognostic marker

KW - Ribosomal protein L19

UR - http://www.scopus.com/inward/record.url?scp=55149101969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55149101969&partnerID=8YFLogxK

U2 - 10.1111/j.1582-4934.2008.00253.x

DO - 10.1111/j.1582-4934.2008.00253.x

M3 - Article

C2 - 18266979

AN - SCOPUS:55149101969

VL - 12

SP - 1936

EP - 1943

JO - Journal of Cellular and Molecular Medicine

JF - Journal of Cellular and Molecular Medicine

SN - 1582-1838

IS - 5B

ER -